Company Melinta Therapeutics Inc Nasdaq
Equities
US58549G1004
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 02/08/20 | |
Susan Blum
DFI | Director of Finance/CFO | 52 | 31/12/15 |
Compliance Officer | 45 | - | |
Jisoo Park
PRN | Corporate Officer/Principal | - | 05/07/21 |
Kristen Allgor
HRO | Human Resources Officer | - | 15/11/20 |
John Harlow
PRN | Corporate Officer/Principal | - | 29/03/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Leff
BRD | Director/Board Member | 55 | 19/04/20 |
Director/Board Member | - | 19/04/20 | |
Director/Board Member | - | 19/04/20 | |
Compliance Officer | 45 | - | |
Chief Executive Officer | 48 | 02/08/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 13,750,691 | 13,578,334 ( 98.75 %) | 0 | 98.75 % |
Company contact information
Melinta Therapeutics, Inc.
389 Interpace Parkway Suite 450
07054, Parsippany
+908-617-1300
http://melinta.comSector
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
-0.03% | 22.25B | |
-13.14% | 22.09B | |
-7.77% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |